BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/13/2023 8:14:59 AM | Browse: 211 | Download: 637
 |
Received |
|
2022-10-28 13:37 |
|
Peer-Review Started |
|
2022-10-28 13:40 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-11-14 08:24 |
|
Revised |
|
2022-11-29 09:48 |
|
Second Decision |
|
2023-02-22 04:09 |
|
Accepted by Journal Editor-in-Chief |
|
2023-02-22 14:11 |
|
Accepted by Company Editor-in-Chief |
|
2023-03-21 06:42 |
|
Articles in Press |
|
2023-03-21 06:42 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-03-27 07:59 |
|
Publish the Manuscript Online |
|
2023-04-13 08:14 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Review |
| Article Title |
Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Supriya Roy and Suneela Dhaneshwar |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Suneela Dhaneshwar, PhD, Director, Pharmacist, Professor, Researcher, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai 410206, Maharashtra, India. suneeladhaneshwar@rediffmail.com |
| Key Words |
Ulcerative colitis; Crohn’s disease; Pouchitis; Dysbiosis; Microbiota; Inflammation |
| Core Tip |
Current treatments for inflammatory bowel disease (IBD), such as corticosteroids and immunosuppressants, have potential adverse effects, and a significant proportion of patients dependent on these treatments are exposed to these associated long-term side effects. The discovery of novel and efficacious therapeutic strategies is a worldwide goal of IBD research, and probiotics, prebiotics, and synbiotics can offer viable solutions. These products offer a novel strategy to deliver beneficial components into the gut and emerge as promising new treatments for IBD, as intestinal dysbiosis has been reported as a major cause of his IBD. The review highlights the current state and action mechanism of these microbial therapies along with various studies that have reported their effectiveness in restoring balance in the gastrointestinal microbiota and thus eventually reducing intestinal inflammation. |
| Publish Date |
2023-04-13 08:14 |
| Citation |
Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. World J Gastroenterol 2023; 29(14): 2078-2100 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i14/2078.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i14.2078 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
